These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 20354663)
1. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy. Dolezel M; Odrazka K; Vaculikova M; Vanasek J; Sefrova J; Paluska P; Zouhar M; Jansa J; Macingova Z; Jarosova L; Brodak M; Moravek P; Hartmann I Strahlenther Onkol; 2010 Apr; 186(4):197-202. PubMed ID: 20354663 [TBL] [Abstract][Full Text] [Related]
2. Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. Dolezel M; Odrazka K; Zouhar M; Vaculikova M; Sefrova J; Jansa J; Paluska P; Kohlova T; Vanasek J; Kovarik J Strahlenther Onkol; 2015 Apr; 191(4):338-46. PubMed ID: 25589224 [TBL] [Abstract][Full Text] [Related]
3. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Michalski JM; Yan Y; Watkins-Bruner D; Bosch WR; Winter K; Galvin JM; Bahary JP; Morton GC; Parliament MB; Sandler HM Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):932-8. PubMed ID: 24113055 [TBL] [Abstract][Full Text] [Related]
4. Intensity modulated radiotherapy (IMRT) or conformational radiotherapy (3D-CRT) with conventional fractionation for prostate cancer: Is there any clinical difference? Viani G; Hamamura AC; Faustino AC Int Braz J Urol; 2019; 45(6):1105-1112. PubMed ID: 31808397 [TBL] [Abstract][Full Text] [Related]
5. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Michalski JM; Bae K; Roach M; Markoe AM; Sandler HM; Ryu J; Parliament MB; Straube W; Valicenti RK; Cox JD Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):14-22. PubMed ID: 19577865 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003 [TBL] [Abstract][Full Text] [Related]
7. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386 [TBL] [Abstract][Full Text] [Related]
8. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy? Sanguineti G; Cavey ML; Endres EJ; Franzone P; Barra S; Parker BC; Marcenaro M; Colman M; Agostinelli S; Foppiano F; Vitale V Strahlenther Onkol; 2006 Sep; 182(9):543-9. PubMed ID: 16944377 [TBL] [Abstract][Full Text] [Related]
10. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts. Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398 [TBL] [Abstract][Full Text] [Related]
11. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. Sujenthiran A; Nossiter J; Charman SC; Parry M; Dasgupta P; van der Meulen J; Cathcart PJ; Clarke NW; Payne H; Aggarwal A Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1253-1260. PubMed ID: 28974414 [TBL] [Abstract][Full Text] [Related]
12. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192 [TBL] [Abstract][Full Text] [Related]
13. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725 [TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Sharma NK; Li T; Chen DY; Pollack A; Horwitz EM; Buyyounouski MK Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):437-44. PubMed ID: 21050673 [TBL] [Abstract][Full Text] [Related]
15. Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results. Valeriani M; Carnevale A; Osti MF; DE Sanctis V; Agolli L; Maurizi Enrici R Radiat Oncol; 2014 Sep; 9():214. PubMed ID: 25260377 [TBL] [Abstract][Full Text] [Related]
16. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959 [TBL] [Abstract][Full Text] [Related]
17. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452 [TBL] [Abstract][Full Text] [Related]
18. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526 [TBL] [Abstract][Full Text] [Related]
19. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study. Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137 [TBL] [Abstract][Full Text] [Related]
20. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Ashman JB; Zelefsky MJ; Hunt MS; Leibel SA; Fuks Z Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):765-71. PubMed ID: 15913914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]